Haemonetics Corporation
HAE
$81.35
$0.600.74%
NYSE
| 09/27/2025 | 06/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.84% | -2.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.84% | -2.78% | |||
| Cost of Revenue | 2.45% | -1.45% | |||
| Gross Profit | 1.43% | -3.67% | |||
| SG&A Expenses | 0.15% | -14.34% | |||
| Depreciation & Amortization | -1.84% | 0.85% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.80% | -6.31% | |||
| Operating Income | 5.95% | 14.20% | |||
| Income Before Tax | 13.54% | -36.15% | |||
| Income Tax Expenses | 13.14% | -12.68% | |||
| Earnings from Continuing Operations | 13.67% | -41.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.67% | -41.31% | |||
| EBIT | 5.95% | 14.20% | |||
| EBITDA | 3.58% | 19.55% | |||
| EPS Basic | 14.93% | -39.99% | |||
| Normalized Basic EPS | 10.73% | 31.67% | |||
| EPS Diluted | 15.71% | -40.61% | |||
| Normalized Diluted EPS | 11.10% | 31.78% | |||
| Average Basic Shares Outstanding | -1.08% | -2.20% | |||
| Average Diluted Shares Outstanding | -1.42% | -2.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||